REFERENCES
- Markman M. The myth of measurable disease in ovarian cancer. J Clin Oncol 2003; 21: 3013–3015
- Vergote I., Rustin G. J., Eisenhauer E. A., Kristensen G B, Pujade-Lauraine E, Parmer M KB, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 2000; 92: 1534–1535
- Moertel C. G., Hanley J. A. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976; 38: 388–394
- Warr D., McKinney S., Tannock I. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol 1984; 2: 1040–1046
- Prefontaine M., Gelfand A. T., Donovan J. T., Powell J. L. Reproducibility of tumor measurements in ovarian cancer: a study of interobserver variability. Gynecol Oncol 1994; 55: 87–90
- Gwyther S., Bolis G., Gore M., ten Bokkel Huinink W, Verweij J, Hudson I R, et al. Experience with independent radiological review during a topotecan trial in ovarian cancer. Ann Oncol 1997; 8: 463–468
- Kaye S. B., Piccart M., Aapro M., Kavanagh J. Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. Eur J Cancer 1995; 31A(Suppl 4)S14–S17
- Eisenhauer E. A., Bokkel Huinink W. W., Swenerton K. D., Gianni L, Myles J, van der berg M AK, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654–2666
- Rose P., Edwards R., Finkler N., Seiden M., Duska L., Krasner C., et al. Phase 3 study: Canfosfamide plus carboplatin vs liposomal doxorubicin as 2nd line therapy of platinum resistant ovarian cancer. J Clin Oncol 2007; 25(21)966s, (18S, Part II), (abstract LBA-5529)
- Hopper K. D., Kasales C. J., Van Slyke M. A., Schwartz T. A., TenHave T. R., Jozefiak J. A. Analysis of interobserver and intraobserver variability in CT tumor measurements. Am J Roentgenol 1996; 167: 851–854
- Davelaar E. M., Bonfrer J. M., Verstraeten R. A., ten Bokkel W., Huinink W., Kenemans P. CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?. Cancer 1996; 78: 118–127
- Morgan R. J., Jr., Speyer J., Doroshow J. H., Margolin K., Rasohko J., Sorich J., et al. Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels. Gynecol Oncol 1995; 58: 79–85
- Markman M., Kennedy A., Webster K., Peterson G., Kulp B., Belinson J. Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant results. Gynecol Oncol 2000; 77: 321–322
- Markman M., Kennedy A., Kim J. Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy. Gynecol Oncol 2001; 83: 593–595
- Azad N. S., Annunziata C. M., Steinberg S. M., Minasian L., Premkumar A., Chow C., Kotz H. L., Kohn E. C. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer 2008; 112: 1726–1732